Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00005995 | AE-941 in Treating Patients With Metastatic Kidney Cancer | PHASE3 | COMPLETED | - | — | — | Oct 1, 2000 | - | Mar 5, 2013 | 1 | Canada |
| Name | Type | Description |
|---|---|---|
| shark cartilage extract AE-941 | DRUG | - |
DISEASE CHARACTERISTICS: Histologically confirmed renal cell adenocarcinoma Disease progression within 16 weeks after first-line therapy, which included interleukin-2 and/or interferon Metastatic disease not amenable to surgery Measurable and/or evaluable disease No more than one line of prior antic...